AMR arises when pathogens undergo mutations or evolutionary changes that diminish the efficacy of antimicrobial agents. Misuse and overuse of antibiotics exacerbate this resistance, rendering infections increasingly challenging to treat. This escalates the risk of disease transmission, contributes to the development of severe diseases and increases mortality rates.
Revium’s liposomal nano-mupirocin is a formulation of the approved, highly effective anti-bacterial drug mupirocin which is currently limited to topical use. The novel proprietary formulation of nano-mupirocin will be administered systemically, providing long circulation time and enhanced delivery of mupirocin to inflammation sites. In several preclinical studies carried out by NIH STI group, nano-mupirocin has demonstrated low minimum inhibitory concentration (MIC) levels as well as excellent efficacy in preclinical models against multiple resistant bacterial strains, including MRSA and VRE.
AMR arises when pathogens undergo mutations or evolutionary changes that diminish the efficacy of antimicrobial agents. Misuse and overuse of antibiotics exacerbate this resistance, rendering infections increasingly challenging to treat. This escalates the risk of disease transmission, contributes to the development of severe diseases and increases mortality rates.
Revium’s liposomal nano-mupirocin is a formulation of the approved, highly effective anti-bacterial drug mupirocin which is currently limited to topical use. The novel proprietary formulation of nano-mupirocin will be administered systemically, providing long circulation time and enhanced delivery of mupirocin to inflammation sites. In several preclinical studies carried out by NIH STI group, nano-mupirocin has demonstrated low minimum inhibitory concentration (MIC) levels as well as excellent efficacy in preclinical models against multiple resistant bacterial strains, including MRSA and VRE.
